Shanghai Junshi Biosciences (HKG:1877, SHA:688180) booked an attributable profit of 25.5 million yuan in the first half of 2026, returning from a loss of 413.4 million yuan a year prior, a Wednesday Hong Kong bourse filing said.
Earnings per share stood at 0.02 yuan, compared with a loss per share of 0.42 yuan in the year-ago period.
Revenue for the interim period increased 45% to 1.70 billion yuan from 1.17 million yuan in the corresponding period of the last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.